Pharmaxis, an Australian biotech focusing on respiratory and autoimmune diseases, said the SFDA accepted for review its application for a clinical trial of Bronchitol™, a treatment for bronchiectasis. The clinical goal of Bronchitol™ is to help patients clear mucus from their lungs by promoting salt and water movement through airway cells. Bronchitol™ is administered twice daily by inhalation. More details...

Stock Symbol: (ASX: PXS; NSDQ: PXSL)